Skip to main content
Elsevier

Handbook of Pharmacogenomics and Precision Medicine

The last decade has seen a revolution in genomics, both in terms of technological innovation and the discovery of genetic markers associated with disease. In parallel, tr… Read more

Purchase options

Sorry, this title is not available for purchase in your country/region.

Description

The last decade has seen a revolution in genomics, both in terms of technological innovation and the discovery of genetic markers associated with disease. In parallel, translational research has moved steadily towards making medicines safer and tailored to the individual.

The Handbook of Pharmacogenomics and Precision Medicine, Second Edition

serves as a comprehensive resource to understand the rapidly advancing field of pharmacogenomics and its goal to deliver the right drug at the right dose to the right patient at the right time. The book provides a detailed but accessible review of the entire field from basic principles to applications in various diseases. Chapters are written by international experts to allow readers from a wide variety of backgrounds, clinical and non-clinical (basic geneticists, pharmacologists, clinicians, trialists, industry personnel, ethicists) to understand the principles underpinning progress in pharmacogenomics and precision medicine, the successes, failures, and challenges ahead.

This new edition has been thoroughly revised in each disease area and updated to cover advances in next generation sequencing, precision oncology, proteomics, metabolomics, stem cells genomics, CRISPR-Cas9 gene editing, and biologics, as well as government and public programs in pharmacogenomics, including the NIH Precision Medicine Initiative, 100K genome project, and the emerging role of the citizen scientist in rare disease study.

Key features

  • Fully updated and expanded to cover new -omics driven technologies and pharmacogenomics of each disease area
  • Provides clinical and non-clinical researchers with practical, actionable information supporting translation of precision medicine
  • Thoroughly explains the fundamentals of genetics, genomic epidemiology, bioinformatics,　pharmacokinetics, and pharmacodynamics
  • Addresses global implications of pharmacogenomics and precision medicine for drug discovery and public health

Readership

Clinical and translational researchers across medical disciplines, genetics, genomics, molecular biology, molecular diagnostics, and bioinformatics; pharmacologists working with clinicians on these studies; genetic counselors; students in genetic, genomics, molecular biology, and pharmaceutical science

Table of contents

Part 1: Introduction1. Pharmacogenomics and Stratified Medicine

Part 2: Basic Genetics2. Basic Genetics: The Cell, Mitosis and Meiosis, and Mendelian Laws3. The Human Genome, Gene Regulation, and Genomic Variation4. Epigenetics

Part 3: Experimental and Discovery Platforms5. Animal Models in Pharmacogenomics6. Human Lymphoblastoid Cell Lines in Pharmacogenomics7. Liver Expression Quantitative Trait Loci (eQTL) and Related 8. Next-Generation Sequencing9. Proteomics10. Metabolomics11. Stem Cells

Part 4: Statistics, Bioinformatics and Databases12. Fundamentals of Complex Trait Genetics and Association Studies13. Bioinformatics: Concepts, Methods, and Data14. PharmGKB: The Pharmacogenomics Knowledgebase

Part 5: Clinical Trials15. Clinical Trials in Pharmacogenomics and Stratified Medicine

Part 6: Fundamental Pharmacogenomics16. CYP450 and Ethnicity17. Pharmacokinetic Pharmacogenomics18. Pharmacodynamic Pharmacogenomics19. MicroRNA: Regulation of P450 and Pharmacogenetics

Part 7: Application in Therapeutics20. Adverse Drug Reactions21. HLA and the Pharmacogenomics of Drug Hypersensitivity22. Drug-Induced Liver Injury23. Hemostasis and Anticoagulants24. Pharmacogenomics of Warfarin25. Pharmacogenomics of Clopidogrel26. Pharmacogenetics of Antidepressant Drugs27. Personalized Medicine of Alzheimer’s Disease28. Asthma29. Rheumatoid Arthritis30. Pharmacogenomics of Oral Antidiabetic Drugs31. Genomics and Pharmacogenomics of Lipid-Lowering Therapies32. Hypertension Pharmacogenomics33. QTc and Sudden Cardiac Death34. Stratified Medicine for Pancreatic Cancer35. Pharmacogenomics in Anesthesia36. Tuberculosis37. Hepatitis C Virus38. Pharmacogenomics of Antifungal Agents39. Advances in Understanding and Treatment of Human African

Part 8: Implementation and Regulatory40. Implementing Clinical Pharmacogenetics: Point-of-Care and Pre-41. Ethical Considerations in Pharmacogenomic Testing and 42. PGx/Biomarker Utilization for Regulatory Decision Making

Part 9: Global Perspective43. Population Diversity and Pharmacogenomics in Africa44. Pharmacogenomics in China45. Pharmacogenomics in Brazil46. Pharmacogenomics in India

Product details

About the editor

SP

Sandosh Padmanabhan

Dr. Sandosh Padmanabhan MD, PhD, FRCP, FAHA, FBHS, FBPhS is a Professor and Physician at the Institute of Cardiovascular and Medical Sciences, University of Glasgow. Dr. Padmanabhan completed his MBBS and MD at JIPMER, Pondicherry, India and was awarded the Gold Medal for MD General Medicine in 1995. His PhD thesis (1999-2003) on G-protein signaling in hypertension was awarded the Bellahouston Medal by the University of Glasgow in 2004, and he received the Austin Doyle Award from the International Society of Hypertension in 2004. Dr. Padmanabhan’s pharmacogenetic genome-wide linkage study led to a BHF Intermediate Fellowship (2006-2009), and he also led a genome wide association analysis of hypertension between 2008 and 2010, resulting in the discovery of a new gene and pathway for hypertension. Dr. Padmanabhan was a visiting fellow to the Broad Institute of Harvard and MIT (2010-2012). Currently, he is a Fellow of the Royal College of Physicians, the British Hypertension Society, and the American Heart Association. His active research areas span the genetics of cardiovascular traits, pharmacogenomics and stratified medicine, and hypertension epidemiology.
Affiliations and expertise
Professor of Cardiovascular Genomics and Therapeutics, BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK